Search results for "Formoterol"

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma.

2008

The Global Initiative for Asthma (GINA) guidelines aim at improving asthma control and preventing future risk. For patients with moderate to severe asthma an inhaled corticosteroid (ICS) or an ICS/long-acting beta2-agonist (LABA) combination with a short-acting beta2-agonist (SABA) as reliever is recommended. Despite the availability of effective maintenance therapies, a large proportion of patients still fail to achieve guideline-defined asthma control, and overuse of SABA reliever medication at the expense of ICS is commonly observed. New simplified treatment approaches may offer a solution and assist physicians to achieve overall asthma control. One such treatment approach, which is reco…

Asthma bronchiale: neue Erkenntnisse und Entwicklungen

2011

In mild asthma low-dose steroid inhalation treatment reduces severe exacerbations and exacerbation associated loss of lung function. In patients with mild asthma, symptom-driven use of a combination of inhaled steroid and short-acting beta-2-sympathomimetics in a single inhaler is feasible. In moderate and severe asthma the fixed combination of formoterol and budesonide can be used a maintenance therapy but also as treatment of acute symptoms. Monotherapy with long-acting beta 2-sympathomimetics should be completely avoided. Long-acting anticholinergic drugs are equally efficacious as long-acting beta-2-sympathomimetics, but have not yet been approved for use in patients with asthma. The co…

Patients' perceptions of well-being using a guided self-management plan in asthma

2004

Summary Asthma can place considerable restrictions on the health-related quality of life of asthma patients and their families; this burden may be greatest when symptoms are not adequately controlled. The Symbicort® Adjustable Maintenance Dosing Programme, consisting of studies from several different countries, compared a guided self-management plan that allows adjustable maintenance dosing using budesonide/formoterol in a single inhaler (Symbicort) with fixed dosing. Quality of life was assessed in three countries, using asthma-specific and generic questionnaires. Clinically relevant improvements in mean quality of life scores were observed from the beginning to the end of the 1-month run-…

Budesonide/Formoterol Maintenance And Reliever Therapy At Two Different Maintenance Doses

2010

Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of th…

2015

Rationale: The QUANTIFY study compared the approved dual bronchodilator QVA149 with the free-dose combination of tiotropium plus formoterol (TIO+FOR) regarding lung function, dyspnoea and health status in patients with moderate-to-severe COPD. This post-hoc analysis reported on the subgroup of pts without ICS background therapy. Methods: This blinded, triple-dummy 26-week study randomised patients to QVA149 110/50 µg OD or TIO 18 µg OD plus FOR 12 µg b.i.d. (1:1). ICS was allowed as background therapy. Endpoints included lung function (trough FEV1), dyspnoea (TDI) and health status (COPD Assessment Test, CAT). Results: Of the 934 pts randomised (QVA149 [N=476] or TIO+FOR [N=458]); 87.9% com…

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

2021

Funder: Global Initiative for Asthma

Budesonide/Formoterol Maintenance And Reliever Therapy At Two Different Maintenance Doses: Effect On Fractional Excretion Of Nitric Oxide (FENO)

2010

Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma

2010

Background: Airway inflammation in asthma involves both large and small airways, and the combination of inhaled corticosteroids (ICS) and long acting beta-2 agonists (LABA) is the mainstay of therapy. Available inhaled combinations differ in terms of drug delivery to the lung and the ability to reach small airways. Aim: To evaluate whether treatment with an extra-fine inhaled combination provides additional effects vs a nonextra-fine combination on airway function. Methods: After a 1- to 4-week run-in period, patients with asthma were randomized to a double blind, double dummy, 12-week treatment with either extra-fine beclomethasone/formoterol (BDP/F) 400/24 lg daily or fluticasone propiona…

Effects of Beclomethasone dipropionate and Formoterol in reducing oxidative stress induced by cigarette smoke extracts and IL-17

2011

Rationale: Oxidative stress is involved in airway inflammatory diseases. Inhaled-corticosteroids reduce airway inflammation and the combination with long-acting β2 agonists enhances this effect. Objective: to investigate whether Cigarette smoke extracts (CSE) and Interleukin-17A (IL-17A) activate airway epithelial cells to release markers of oxidative/nitrosative stress and to investigate the effect of beclomethasone dipropionate (BDP) and formoterol. Methods: Human bronchial epithelial cells (16HBE) were stimulated with different concentrations of CSE (from 0 to 10%) to evaluate the expression of IL-17 receptor (IL-17R). 16HBE were also stimulated with CSE (2.5%) with and withouth rhIL-17A…

Neuroendocrine Modulation of IL-27 in Macrophages

2017

Abstract Heterodimeric IL-27 (p28/EBV-induced gene 3) is an important member of the IL-6/IL-12 cytokine family. IL-27 is predominantly synthesized by mononuclear phagocytes and exerts immunoregulatory functional activities on lymphocytic and nonlymphocytic cells during infection, autoimmunity or neoplasms. There is a great body of evidence on the bidirectional interplay between the autonomic nervous system and immune responses during inflammatory disorders, but so far IL-27 has not been defined as a part of these multifaceted neuroendocrine networks. In this study, we describe the role of catecholamines (as mediators of the sympathetic nervous system) related to IL-27 production in primary …